← Back

Wire · opportunities

Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA ...

Published

17 November 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

India

◆ Source

Read at morningstar.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

Cardio Diagnostics is unveiling data to support its AI-driven technology for detecting non-obstructive coronary artery disease (NOCAD), aiming for FDA Breakthrough Device designation and preparing to launch testing in India via partnerships.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You must plan for new diagnostic rules as Cardio Diagnostics advances FDA clearance for detecting hidden heart disease, opening access beyond typical tests. This shift lets you target overlooked patients with simpler blood tests and positions India as your first major overseas market.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Healthcardiovascular-diseasenocardfda-breakthrough-deviceindia-launchprecision-medicineai-healthtech